Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.

@article{Miller2010ConsensusSC,
  title={Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.},
  author={David T. Miller and Margaret P Adam and Swaroop Aradhya and Leslie G. Biesecker and Arthur R. Brothman and Nigel P. Carter and Deanna M. Church and John Anthony Crolla and Evan E. Eichler and Charles J. Epstein and William A Faucett and Lars Feuk and Jan M Friedman and Ada Hamosh and Laird G. Jackson and Erin B Kaminsky and Klaas Kok and Ian D. Krantz and Robert M. Kuhn and Charles Lee and James Ostell and Carla Rosenberg and Stephen W. Scherer and Nancy B. Spinner and Dimitri J Stavropoulos and James H. Tepperberg and Erik C. Thorland and Joris Robert Vermeesch and Darrel J. Waggoner and Michael S. Watson and Christa L. Martin and David H. Ledbetter},
  journal={American journal of human genetics},
  year={2010},
  volume={86 5},
  pages={749-64}
}
Chromosomal microarray (CMA) is increasingly utilized for genetic testing of individuals with unexplained developmental delay/intellectual disability (DD/ID), autism spectrum disorders (ASD), or multiple congenital anomalies (MCA). Performing CMA and G-banded karyotyping on every patient substantially increases the total cost of genetic testing. The International Standard Cytogenomic Array (ISCA) Consortium held two international workshops and conducted a literature review of 33 studies… CONTINUE READING
Highly Influential
This paper has highly influenced 39 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 12 times over the past 90 days. VIEW TWEETS
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com